We reviewed the case records of all children admitted to the Aga Khan University Hospital (AKUH) with a diagnosis of Haemolytic Uremic Syndrome (HUS) over a 7 year period (July, 1988-June, 1995). A total of 33 patients were admitted to the Pediatric ward at (AKUH) with a median age of 16 months (range 4 months-9 years). 97% cases identified were of the classic variety and no familial case was identified. The mean duration of illness was 27 days, 39% had an illness > 28 days. Diarrhoea and prior antibiotic used was in 97% patients. Oliguria at admission was seen in 52.5% and seizures in 24% of cases. Thrombocytopenia, anemia and leucocytosis at admission was present in > 72% of children. Hyponatremia was present in 42% while acidosis, hypocalcemia and hyperkalemia was seen in 30% of children. Despite optimal management and peritoneal dialysis in 14 (42%) patients, 8 (24%) died. No specific relationship was found between mortality and any clinical or laboratory feature at presentation. Our data highlights the importance of HUS in the Pediatric age group and the need for further studies to delineate risk factors for adverse outcome.

Download full-text PDF

Source

Publication Analysis

Top Keywords

aga khan
8
khan university
8
illness days
8
haemolytic uraemic
4
uraemic syndrome
4
syndrome childhood
4
childhood experience
4
experience years
4
years aga
4
university reviewed
4

Similar Publications

Bcr-Abl plays a central role in the development of chromosome positive leukaemia. Chronic Myeloid leukaemia occurs due to increase proliferation and resistance to apoptosis by Bcr-Abl positive cells. Imatinib (STI571) is the first drug in the family of Bcr-Abl tyrosine kinase inhibitors while Nilotinib (AMN107) and Dasatinib (BMS-345825) are second generation drugs that are intended to have less resistance and intolerance than imatinib.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!